SABCS 2022 Conference Coverage


 

SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rates of Adverse Events of Sacituzumab Govitecan vs. Treatment of Physician’s Choice in HR+/HER2- mBC

74 views
December 19, 2022
Comments 0
Login to view comments. Click here to Login